Spina bifida natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Spina bifida}} {{CMG}}; {{AE}} {{MMJ}} ==Overview== If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifesta...")
 
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 5: Line 5:


==Overview==
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Prognosis of patients with spina bifida is generally poor. Early clinical features of spina bifida include: Weakness or [[paralysis]] in the legs, [[Urinary incontinence]], [[Bowel]] incontinence, [[Sensation]] problems in the [[lower extremity]], [[Motor]] problems in the [[lower extrimity]] and [[Hydrocephalus]]. If left untreated, 50% of patients with congenital anomalies, especially spina bifida may die soon after birth in the underdeveloped countries. [[Renal failure]] is the commonest cause of death in patients with spina bifida. Common complications of [disease name] include: [[Cardiac]] disease, [[Respiratory disease]], [[Suicidality]] and [[Cancer]].


OR
== Natural History, Complications and Prognosis==
 
*Prognosis of patients with spina bifida is generally poor.
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Early clinical features include:<ref name="pmid10350196">{{cite journal |vauthors=Soonawala N, Overweg-Plandsoen WC, Brouwer OF |title=Early clinical signs and symptoms in occult spinal dysraphism: a retrospective case study of 47 patients |journal=Clin Neurol Neurosurg |volume=101 |issue=1 |pages=11–4 |date=March 1999 |pmid=10350196 |doi= |url=}}</ref><ref name="pmid4898641">{{cite journal |vauthors=Bannur BB, Purandare GM |title=Microbial production of L-lysine |journal=Hindustan Antibiot Bull |volume=11 |issue=3 |pages=191–205 |date=February 1969 |pmid=4898641 |doi= |url=}}</ref><ref name="pmid2647936">{{cite journal |vauthors=Horton D, Barnes P, Pendleton BD, Pollay M |title=Spina bifida occulta: early clinical and radiographic diagnosis |journal=J Okla State Med Assoc |volume=82 |issue=1 |pages=15–9 |date=January 1989 |pmid=2647936 |doi= |url=}}</ref>
 
**Weakness or [[paralysis]] in the legs.
OR
**[[Urinary incontinence]]
 
**[[Bowel]] incontinence
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
**[[Sensation]] problems in the [[lower extremity]]
==Natural History, Complications, and Prognosis==
**[[Motor]] problems in the [[lower extrimity]]
 
**[[Hydrocephalus]]
===Natural History===
*If left untreated, 50% of patients with congenital anomalies, especially spina bifida may die soon after birth in the underdeveloped countries.<ref name="pmid2441590">{{cite journal |vauthors=Kozlowski BW, Taylor ML, Baer MT, Blyler EM, Trahms C |title=Anticonvulsant medication use and circulating levels of total thyroxine, retinol binding protein, and vitamin A in children with delayed cognitive development |journal=Am. J. Clin. Nutr. |volume=46 |issue=2 |pages=360–8 |date=August 1987 |pmid=2441590 |doi=10.1093/ajcn/46.2.360 |url=}}</ref>
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.  
*[[Renal failure]] is the commonest cause of death in patients with spina bifida.<ref name="pmid2441590">{{cite journal |vauthors=Kozlowski BW, Taylor ML, Baer MT, Blyler EM, Trahms C |title=Anticonvulsant medication use and circulating levels of total thyroxine, retinol binding protein, and vitamin A in children with delayed cognitive development |journal=Am. J. Clin. Nutr. |volume=46 |issue=2 |pages=360–8 |date=August 1987 |pmid=2441590 |doi=10.1093/ajcn/46.2.360 |url=}}</ref>
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
*Common complications of [disease name] include:<ref name="pmid2441590">{{cite journal |vauthors=Kozlowski BW, Taylor ML, Baer MT, Blyler EM, Trahms C |title=Anticonvulsant medication use and circulating levels of total thyroxine, retinol binding protein, and vitamin A in children with delayed cognitive development |journal=Am. J. Clin. Nutr. |volume=46 |issue=2 |pages=360–8 |date=August 1987 |pmid=2441590 |doi=10.1093/ajcn/46.2.360 |url=}}</ref>
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
**[[Cardiac]] disease
 
**[[Respiratory disease]]
===Complications===
**[[Suicidality]]
*Common complications of [disease name] include:
**[[Cancer]]
**[Complication 1]
**[Complication 2]
**[Complication 3]
 
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.


==References==
==References==

Latest revision as of 18:26, 6 February 2019

Spina bifida Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Spina Bifida from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electroencephalogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Spina bifida natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Spina bifida natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Spina bifida natural history, complications and prognosis

CDC on Spina bifida natural history, complications and prognosis

Spina bifida natural history, complications and prognosis in the news

Blogs on Spina bifida natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Spina bifida natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

Prognosis of patients with spina bifida is generally poor. Early clinical features of spina bifida include: Weakness or paralysis in the legs, Urinary incontinence, Bowel incontinence, Sensation problems in the lower extremity, Motor problems in the lower extrimity and Hydrocephalus. If left untreated, 50% of patients with congenital anomalies, especially spina bifida may die soon after birth in the underdeveloped countries. Renal failure is the commonest cause of death in patients with spina bifida. Common complications of [disease name] include: Cardiac disease, Respiratory disease, Suicidality and Cancer.

Natural History, Complications and Prognosis

References

  1. Soonawala N, Overweg-Plandsoen WC, Brouwer OF (March 1999). "Early clinical signs and symptoms in occult spinal dysraphism: a retrospective case study of 47 patients". Clin Neurol Neurosurg. 101 (1): 11–4. PMID 10350196.
  2. Bannur BB, Purandare GM (February 1969). "Microbial production of L-lysine". Hindustan Antibiot Bull. 11 (3): 191–205. PMID 4898641.
  3. Horton D, Barnes P, Pendleton BD, Pollay M (January 1989). "Spina bifida occulta: early clinical and radiographic diagnosis". J Okla State Med Assoc. 82 (1): 15–9. PMID 2647936.
  4. 4.0 4.1 4.2 Kozlowski BW, Taylor ML, Baer MT, Blyler EM, Trahms C (August 1987). "Anticonvulsant medication use and circulating levels of total thyroxine, retinol binding protein, and vitamin A in children with delayed cognitive development". Am. J. Clin. Nutr. 46 (2): 360–8. doi:10.1093/ajcn/46.2.360. PMID 2441590.

Template:WH Template:WS